Mammoth Biosciences

Mammoth Biosciences: Series D Funding Round

Mammoth Biosciences has successfully raised $195M in Series D funding, reaching a valuation of $1B.

Company Overview

CRISPR-based diagnostics and therapeutics

Funding Details

The Series D round was led by Decheng Capital, with participation from Greenoaks Capital, Mayfield, NFX, 8VC, Plum Alley Ventures.

Company Information

• Headquarters: 3478 Buskirk Avenue, Pleasant Hill, CA 94523
• Founded: 2017
• Employees: 150+
• Category: Biotech

Investment

Mammoth Biosciences plans to use the funds to accelerate product development, expand its team, and scale operations globally.

About the Investors

• Decheng Capital: Verified investor in Series D
• Greenoaks Capital: Verified investor in Series D
• Mayfield: Verified investor in Series D
• NFX: Verified investor in Series D
• 8VC: Verified investor in Series D
• Plum Alley Ventures: Verified investor in Series D